Clinical study for the effects of sacubitril/valsartan on sST2 and Gal-3 in patients with chronic heart failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026530

Enrollment

Unknown

Registered

2019-10-13

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

sacubitril/valsartan group:sacubitril/valsartan

Control group:Not stated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic heart failure

Exclusion criteria

Exclusion criteria: 1. having a history of angioneurotic edema; 2. severe bilateral renal artery stenosis; 3. pregnant or lactating women; 4. severe liver damage (child-pugh grade C), biliary cirrhosis and cholestasis; 5. known allergy to ARB or ARNI.

Design outcomes

Primary

Measure	Time frame
sST2;Gal-3;	—

Countries

China

Contacts

Public ContactDai Shuren

Yongchuan Hospital Of Chongqing Medical University

163dsr@163.com+86 023-85381656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026